Yellow Fever Vaccine-Related Neurotropic Disease in Brazil Following Immunization with 17DD

被引:2
|
作者
Gandolfi, Flora de Andrade [1 ,2 ]
Estofolete, Cassia Fernanda [1 ,3 ]
Wakai, Marcia Catelan [2 ,4 ]
Negri, Andreia Francesli [3 ]
Barcelos, Michela Dias [3 ]
Vasilakis, Nikos [5 ,6 ,7 ,8 ,9 ,10 ]
Nogueira, Mauricio Lacerda [1 ,3 ,5 ]
机构
[1] Fac Med Sao Jose do Rio Preto FAMERP, Lab Pesquisas Virol LPV, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil
[2] Hosp Crianca & Maternidade Sao Jose do Rio Preto, BR-15091240 Sao Jose Do Rio Preto, SP, Brazil
[3] Hosp Base Sao Jose do Rio Preto, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil
[4] Municipal Hlth Dept, BR-15084010 Sao Jose Do Rio Preto, SP, Brazil
[5] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA
[6] Univ Texas Med Branch, Dept Prevent Med & Populat Hlth, Galveston, TX 77555 USA
[7] Univ Texas Med Branch, Ctr Vector Borne & Zoonot Dis, Galveston, TX 77555 USA
[8] Univ Texas Med Branch, Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA
[9] Univ Texas Med Branch, Ctr Trop Dis, Galveston, TX 77555 USA
[10] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA
基金
巴西圣保罗研究基金会; 美国国家卫生研究院;
关键词
yellow fever; vaccine; serious adverse events; neurotropic disorder; 17D-204; MENINGOENCEPHALITIS;
D O I
10.3390/vaccines11020445
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The disease burden of yellow fever virus infection (YFV) is quite high in the tropics where vaccination coverage is low. To date, vaccination is the most effective control strategy to mitigate and eliminate the burden of YF disease. The licensed YF vaccines are safe and effective and serious adverse events are rare. Herein, we report three cases of neurological syndrome, compatible with meningoencephalitis following 17DD vaccination. In all cases, YFV-specific IgM antibodies were detected in the cerebrospinal fluid. Our observations confirm the development of YF vaccine-associated neurotropic disease, a rare serious adverse event, from which all three patients have fully recovered without any long-term sequelae. This report reinforces the need for awareness among health professionals to recognize and effectively manage such events in a timely manner.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Description of a Prospective 17DD Yellow Fever Vaccine Cohort in Recife, Brazil
    de Melo, Andrea Barbosa
    da Silva, Maria da Paz C.
    Magalhaes, Maria Cecilia F.
    Vega Gonzales Gil, Laura Helena
    Freese de Carvalho, Eduardo M.
    Braga-Neto, Ulisses M.
    Bertani, Giovani Rota
    Marques, Ernesto T. A., Jr.
    Cordeiro, Marli Tenorio
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2011, 85 (04): : 739 - 747
  • [2] Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys
    Marchevsky, RS
    Freire, MS
    Coutinho, ESF
    Galler, R
    VIROLOGY, 2003, 316 (01) : 55 - 63
  • [3] Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases
    Vasconcelos, PFC
    Luna, EJ
    Galler, R
    Silva, LJ
    Coimbra, TL
    Barros, VLRS
    Monath, TP
    Rodigues, SG
    Laval, C
    Costa, ZG
    Vilela, MFG
    Santos, CLS
    Papaiordanou, CMO
    Alves, VAF
    Andrade, LD
    Sato, HK
    Rosa, EST
    Froguas, GB
    Lacava, E
    Almeida, LMR
    Cruz, ACR
    Rocco, IM
    Santos, RTM
    Oliva, OFP
    LANCET, 2001, 358 (9276): : 91 - 97
  • [4] An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures
    Pereira, Renata C.
    Silva, Andrea N. M. R.
    Souza, Marta Cristina O.
    Silva, Marlon V.
    Neves, Patricia P. C. C.
    Silva, Andrea A. M. V.
    Matos, Denise D. C. S.
    Herrera, Miguel A. O.
    Yamamura, Anna M. Y.
    Freire, Marcos S.
    Gaspar, Luciane P.
    Caride, Elena
    VACCINE, 2015, 33 (35) : 4261 - 4268
  • [5] Duration of immunity in recipients of two doses of 17DD yellow fever vaccine
    Collaborative group for studies on yellow fever vaccines
    VACCINE, 2019, 37 (35) : 5129 - 5135
  • [6] The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil
    Suzano, CES
    Amaral, E
    Sato, HK
    Papaiordanou, PM
    VACCINE, 2006, 24 (09) : 1421 - 1426
  • [7] MOLECULAR ANALYSIS OF YELLOW-FEVER VIRUS 17DD VACCINE STRAIN
    POST, PR
    SANTOS, CND
    CARVALHO, R
    LOPES, OS
    GALLER, R
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 1991, 86 (02): : 239 - 246
  • [8] Risk of fatal adverse events associated with 17DD yellow fever vaccine
    Struchiner, CJ
    Luz, PM
    Dourado, I
    Sato, HK
    Aguiar, SG
    Ribeiro, JGL
    Soares, RCR
    Codeço, TC
    EPIDEMIOLOGY AND INFECTION, 2004, 132 (05): : 939 - 946
  • [9] Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil
    Galler, R
    Pugachev, KV
    Santos, CLS
    Ocran, SW
    Jabor, AV
    Rodrigues, SG
    Marchevsky, RS
    Freire, MS
    Almeida, LFC
    Cruz, ACR
    Yamamura, AMY
    Rocco, IM
    da Rosa, EST
    Souza, LTM
    Vasconcelos, PFC
    Guirakhoo, F
    Monath, TP
    VIROLOGY, 2001, 290 (02) : 309 - 319
  • [10] Immune response induced by standard and fractional doses of 17DD yellow fever vaccine
    Abdala-Torres, Thais
    Campi-Azevedo, Ana Carolina
    da Silva-Pereira, Rosiane Aparecida
    dos Santos, Luara Isabela
    Henriques, Priscilla Miranda
    Costa-Rocha, Ismael Artur
    Otta, Dayane Andriotti
    Peruhype-Magalhaes, Vanessa
    Teixeira-Carvalho, Andrea
    Araujo, Marcio Sobreira Silva
    Fernandes, Eder Gatti
    Sato, Helena Keico
    Fantinato, Francieli Fontana Sutile Tardetti
    Domingues, Carla Magda Allan Santos
    Kallas, Esper Georges
    Tomiyama, Helena Tomoko Iwashita
    Lemos, Jandira Aparecida Campos
    Coelho-dos-Reis, Jordana Grazziela
    de Lima, Sheila Maria Barbosa
    Schwarcz, Waleska Dias
    Azevedo, Adriana de Souza
    Trindade, Gisela Freitas
    Bom, Ana Paula Dinis Ano
    da Silva, Andrea Marques Vieira
    Fernandes, Camilla Bayma
    Camacho, Luiz Antonio Bastos
    Maia, Maria de Lourdes de Sousa
    Martins-Filho, Olindo Assis
    do Antonelli, Lis Ribeiro do Valle
    NPJ VACCINES, 2024, 9 (01)